Previous 10 | Next 10 |
2024-02-12 08:27:22 ET More on Pre-market losers & stocks. Manchester United: Public Market Discount Manchester United: A Historic Giant Facing Valuation Challenges And Why It's Time To Sell Knives Are Out For Vuzix Corporation Manchester United appoints ...
2024-02-12 07:52:37 ET More on AN2 Therapeutics Seeking Alpha’s Quant Rating on AN2 Therapeutics Historical earnings data for AN2 Therapeutics Financial information for AN2 Therapeutics Read the full article on Seeking Alpha For further details...
-Enrolled patients allowed to continue on study- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the company’s decision to ...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the Oppenheimer 34 th Ann...
2024-01-06 02:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-21 16:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-10 09:28:29 ET More on AN2 Therapeutics AN2 Therapeutics director and 10% owner disposes stake in the company AN2 Therapeutics prices $70.0 million stock offering Seeking Alpha’s Quant Rating on AN2 Therapeutics Historical earnings data for AN2...
Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease On track to announce Phase 2 clinical data summer 2024 Cash and investments of $150.2 million at September 30, 2023; c...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
AN2 Therapeutics Inc. (ANTX) is expected to report $-0.63 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determi...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...